| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36310ab39fe797510fbf5c0408149b4f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate |
2009-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a48126798911423d95900d4b5578c0e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecd3b2d3bba88f1a1dd4e6bdb48afe6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed0883c99414948f58ea3ee19b6c23af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e27b963454b4c319426f2f57237ff53a |
| publicationDate |
2016-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160096721-A |
| titleOfInvention |
Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes |
| abstract |
A component capable of inhibiting one or more of the histone deacetylase family for the therapeutic treatment of Philadelphia chromosome-negative myeloproliferative syndrome (intrinsic erythropoiesis, essential hyperplasia or idiopathic myelofibrosis) (histone diacetylase Inhibitor). ≪ / RTI > The dose of the above-mentioned ingredients is significantly lower than that normally used for the management of other tumor syndromes and can be 10 to 150 mg / day / patient. |
| priorityDate |
2008-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |